Product Description:
Nindanix is indicated for the treatment of locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) adenocarcinoma type in combination with docetaxel for the treatment of adult patients after the failure of first-line chemotherapy.
Product Features:
| Product Name | Nindanix |
| Generic Name | Nintedanib |
| Formulation | Capsule |
| Available Pack Size | 80 & 50 Capsule |
| Available Strength | 100 mg, 150 mg |
| Registrations | Available |
